Diabetes

• What are Therapeutic Market Outlooks?
• Available Reports
• Pricing and Deliverables
• TMO Sample Pages

Tables and Figures - Diabetes

• Page 5: Glycemic and Lipids Control Recommendations for Adults with Diabetes
• Page 5: Criteria for the Diagnosis of Diabetes
• Page 6: CDC Estimates of Diabetes Percentiles (Age>20)
• Page 6: AVOS Population Projections by Year, 2006-2013
• Page 7: U.S. Diabetes Patient Population Model
• Page 8: Drug Treatment Options by Class for Diabetes
• Page 10: Types of Insulins
• Page 12: U.S. Anti-Diabetes Market Model - Patient Years of Therapy
• Page 13: U.S. Anti-Diabetes Market Model - Market Share
• Page 14: U.S. Anti-Diabetes Market Model - Revenue
• Page 15: U.S. Anti-Diabetes Market Model - Price per Annual Course of Therapy
• Page 16: Pattern of Treatment for Type 1 Diabetes
• Page 16: Pattern of Treatment for Type 2 Diabetes
• Page 18: Physician Efficacy and Side Effect Comparison
• Page 19: Physician Product Ratings
• Page 20: 2007 Share of Prescriptions, 6-Year Forecasted Trend, and Major Trend Drivers
• Page 22: Marketed Products in the U.S.
• Page 23: Timeline of Major Market Events
• Page 25: Actos Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, and Commercial Strength
• Page 26: Actos Franchise - Prescribing Trend
• Page 28: Avandia Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, Commercial Strength, and Avandia Franchise - Prescribing Trend
• Page 31: Januvia Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, Commercial Strength, and Januvia Franchise - Prescribing Trend
• Page 33: Byetta Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, and Commercial Strength
• Page 35: Prandin/NovoNorm Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, and Commercial Strength
• Page 37: Exubera Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, and Commercial Strength
• Page 39: Lantus/Levemir Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, and Commercial Strength
• Page 41: Humalog/Novolog/Apidra Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, and Commercial Strength
• Page 43: Humulin/Novolin Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, Commercial Strength, and Prescribing Trend
• Page 45: Byetta LAR/Liraglutide Revenue Model, U.S. Market Share Forecast, and U.S. Revenue Forecast
• Page 47: Saxagliptin/Galvus/SYR-322 Revenue Model, U.S. Market Share Forecast, and U.S. Revenue Forecast
• Page 49: AIR/AERx/Technosphere Insulin & Oral-lyn Revenue Model, U.S. Market Share Forecast, and U.S. Revenue Forecast
• Page 52: Clinical Success Rates of Anti-Diabetes Agents: 1995-Present
• Page 53: Drugs in Development
• Page 54: Drugs in Development (Continued)